U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Other Gastrointestinal, CTCAE

MedGen UID:
294704
•Concept ID:
C1560441
•
Finding

Professional guidelines

PubMed

Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Scherz A, Shelan M, Soldatovic I, Yojena CKK, Aebersold DM, Lössl K
Radiat Oncol 2017 Dec 22;12(1):202. doi: 10.1186/s13014-017-0938-1. PMID: 29273076Free PMC Article
Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS, Frenette CT, Keefe SM, Stein SM
Semin Oncol 2014 Feb;41 Suppl 2:S1-S16. Epub 2014 Jan 9 doi: 10.1053/j.seminoncol.2014.01.001. PMID: 24576654

Recent clinical studies

Etiology

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X, Xiao YT, Yang Y, Ye Y, Chang Y, Jiang L, Eftekhar M, Ren S, Zhang H
Cancer Control 2022 Jan-Dec;29:10732748221120462. doi: 10.1177/10732748221120462. PMID: 35980734Free PMC Article
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.
Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, Zanini A, Amoroso V, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A
Support Care Cancer 2022 Aug;30(8):6955-6961. Epub 2022 May 11 doi: 10.1007/s00520-022-07091-6. PMID: 35538327
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Singh K, Sathyamurthy A, Ramireddy JK, Ram TS
J Gastrointest Cancer 2022 Mar;53(1):161-169. Epub 2021 Jan 5 doi: 10.1007/s12029-020-00580-z. PMID: 33400211
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA
Clin Oncol (R Coll Radiol) 2018 Jul;30(7):418-426. Epub 2018 Mar 28 doi: 10.1016/j.clon.2018.02.067. PMID: 29602584

Diagnosis

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Safety profile of G-CSF in chemotherapy-induced neutropenia: A prospective observational study in Eastern India.
Deb U, Mukhopadhyay S, Banerjee S, Biswas S
Indian J Cancer 2022 Oct-Dec;59(4):493-498. doi: 10.4103/ijc.IJC_982_19. PMID: 33753622
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R
ESMO Open 2021 Oct;6(5):100231. Epub 2021 Sep 9 doi: 10.1016/j.esmoop.2021.100231. PMID: 34509802Free PMC Article
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN, Chan HL, Mok TS, Wong GL
Cancer Med 2020 Oct;9(19):7052-7061. Epub 2020 Aug 11 doi: 10.1002/cam4.3378. PMID: 32780516Free PMC Article
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.
De Marchi P, Melendez ME, Laus AC, Kuhlmann PA, de Carvalho AC, Arantes LMRB, Evangelista AF, Andrade ES, de Castro G Junior, Reis RM, Carvalho AL, de Souza Viana L
Oral Oncol 2019 Nov;98:48-52. Epub 2019 Sep 17 doi: 10.1016/j.oraloncology.2019.09.013. PMID: 31539757

Therapy

Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML
JAMA Oncol 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. PMID: 36633877Free PMC Article
Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X, Xiao YT, Yang Y, Ye Y, Chang Y, Jiang L, Eftekhar M, Ren S, Zhang H
Cancer Control 2022 Jan-Dec;29:10732748221120462. doi: 10.1177/10732748221120462. PMID: 35980734Free PMC Article
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.
Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, Zanini A, Amoroso V, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A
Support Care Cancer 2022 Aug;30(8):6955-6961. Epub 2022 May 11 doi: 10.1007/s00520-022-07091-6. PMID: 35538327
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Singh K, Sathyamurthy A, Ramireddy JK, Ram TS
J Gastrointest Cancer 2022 Mar;53(1):161-169. Epub 2021 Jan 5 doi: 10.1007/s12029-020-00580-z. PMID: 33400211

Prognosis

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study.
Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, Zanini A, Amoroso V, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A
Support Care Cancer 2022 Aug;30(8):6955-6961. Epub 2022 May 11 doi: 10.1007/s00520-022-07091-6. PMID: 35538327
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G
Eur J Nucl Med Mol Imaging 2021 Sep;48(10):3260-3267. Epub 2021 Feb 18 doi: 10.1007/s00259-021-05236-z. PMID: 33604690Free PMC Article
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA
Clin Oncol (R Coll Radiol) 2018 Jul;30(7):418-426. Epub 2018 Mar 28 doi: 10.1016/j.clon.2018.02.067. PMID: 29602584
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F
Anticancer Drugs 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. PMID: 28296649

Clinical prediction guides

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML
JAMA Oncol 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. PMID: 36633877Free PMC Article
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA
Clin Oncol (R Coll Radiol) 2018 Jul;30(7):418-426. Epub 2018 Mar 28 doi: 10.1016/j.clon.2018.02.067. PMID: 29602584
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F
Anticancer Drugs 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. PMID: 28296649
Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS, Frenette CT, Keefe SM, Stein SM
Semin Oncol 2014 Feb;41 Suppl 2:S1-S16. Epub 2014 Jan 9 doi: 10.1053/j.seminoncol.2014.01.001. PMID: 24576654

Recent systematic reviews

Interventions for Concerning Patient-Reported Outcomes in Routine Cancer Care: A Systematic Review.
Sampieri G, Li H, Ataalla P, Merriman K, Noel CW, Hallet J, Coburn N, Karam I, Smoragiewicz M, Wong B, Fu R, Eskander A
Ann Surg Oncol 2024 Feb;31(2):1148-1170. Epub 2023 Nov 23 doi: 10.1245/s10434-023-14576-z. PMID: 37996640

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...